Abstract
Chronic obstructive pulmonary disease (COPD) is a serious respiratory disease with
high morbidity, disability and mortality worldwide. Every year, many people die from the disease
or its comorbidities. Osteoporosis is a common complication of COPD, which can lead to increased
fractures in COPD patients, aggravate the disease, and then bring great pain and burden
to patients. The possible factors leading to osteoporosis in COPD patients include systemic inflammation,
corticosteroid use, vitamin D deficiency, physical inactivity, tobacco exposure, lower
bone mineral density, hypogonadism, hypoxia, and anemia. In clinical practice, the rate of diagnosis
and treatment of osteoporosis in patients with COPD is low. Several studies demonstrated
that treating osteoporosis with bisphosphonates could improve bone density, make breathing easier,
and improve the quality of life of COPD patients. However, no studies have examined the effect
of anti-osteoporosis therapy on fracture prevention in COPD patients. More research is needed
to clarify how to implement holistic medical interventions in COPD patients with osteoporosis.
We recommend that every COPD patient be screened for osteoporosis and treated with standard
medications for primary osteoporosis.
Keywords:
Chronic obstructive pulmonary disease, osteoporosis, fracture, comorbidities, physical inactivity tobacco exposure hypogonadism, inflammation.
[9]
Jesús Recio, I.; Díez-Manglano, J.; Francisco López, G.; José Antonio, D.P.; Pere, A.; José Manuel, V.A. Management of the COPD patient with comorbidities: An experts recommendation document. Int. J. Chron. Obstruct. Pulmon. Dis., 2020, 15, 1015-1037.
[13]
Zhang, M.; Yan, D.W.; Zhang, Q.L. The effect for COPD patients with osteoporosis and on lung function using alondronate. Zhongguo Guzhi Shusong Zazhi, 2004, 10, 340-343.
[14]
Yuan, H.; Li, J.; Weng, Y.Q. The efficacy of zoledronic acid on osteoporosis and pulmonary function in COPD patients. Zhongguo Guzhi Shusong Zazhi, 2019, 25, 358-361.
[15]
OuYang, J.F.; Li, B.Q.; Xuan, W.H. Clinical effectiveness of Zoledronic acid in the treatlnent Of senile osteoporosis patients with COPD. Zhongguo Guzhi Shusong Zazhi, 2019, 25, 1142-1145.
[16]
Liu, L.L.; Zhang, C.C.; Xiong, W. Effect of Alendronate combined with Caltrate D on COPD complicated with osteoporosis and on pulmonary function. Zhongguo Laonianxue Zazhi, 2021, 41, 3426-3429.
[17]
Chen Yi, W.; Ramsook, A.H.; Coxson, H.O. Prevalence and risk factors for ostoporosis in individuaIs with chronic obstructive pulmonary disease: A systematic review and meta-analysjs. Chest, 2019, 156, 1092-1110.
[28]
Huo, J The research about serum IL6 and c-reactive protein in elderly Osteoporosis patients with COPD. Chinese Med. Clin., 2018, 18, 2104-2106.
[29]
Yang, J.J.; Cheng, C.Q.; Zhao, G.Y. Chronic obstructive pulmonary disease and osteoporosis. Zhongguo Guzhi Shusong Zazhi, 2020, 26, 1378-1381.
[48]
Gazzotti, M.R. Frequency of osteopomsis and vertebral fractures in chronic obstmctive pulmonary disease(COPD) patients. Arch. Bronconeumol., 2019, 55, 252-257.